Fulcrum Therapeutics, Inc.
FULCFulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapies for patients with genetically defined rare diseases.
Table of contents
Earnings
Next report
Aug 4, 2026 (In 6 days)Competitors
By market cap
By revenue growth
Profile
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapies for patients with genetically defined rare diseases. The company utilizes a proprietary discovery approach to identify and validate cellular drug targets that modulate gene expression to treat the root causes of these conditions. Its primary focus is on advancing its lead candidate for the treatment of sickle cell disease and expanding its pipeline through internal discovery and strategic licensing.
A clinical-stage innovator in the sickle cell disease market, focusing on oral small molecule alternatives to complex gene therapies and existing treatments like hydroxyurea.
Questions, answered.
- What is Fulcrum Therapeutics, Inc.'s market cap?
- Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of $248.5M and trades on NASDAQ.
- Who are Fulcrum Therapeutics, Inc.'s competitors?
- Fulcrum Therapeutics, Inc.'s key competitors include Bristol-Myers Squibb, Vertex Pharmaceuticals, Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does Fulcrum Therapeutics, Inc. partner with?
- Fulcrum Therapeutics, Inc.'s notable partners include CAMP4 Therapeutics, Children’s Medical Center Corporation.
- Where is Fulcrum Therapeutics, Inc. headquartered?
- Fulcrum Therapeutics, Inc. is headquartered in United States of America and employs approximately 89 people. It has been publicly traded since 2019.